Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cidara Therapeutics, Inc. - Common Stock (NQ:CDTX)

218.41 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cidara Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything ↗
Via MarketBeat
News headline image
Why Bain Capital Is Selling Shares of This Biotech Stock Now ↗
Bain Capital sold $20 million worth of Pharvaris stock during the third quarter. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗
One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks. 
Via The Motley Fool
News headline image
Top 2 Health Care Stocks That May Fall Off A Cliff This Month ↗
 
Via Benzinga
Cidara Therapeutics Stock Rockets Over 700% This Year — Then Wall Street Turns Neutral On Merck Takeover ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
Cidara Therapeutics Granted FDA Breakthrough Therapy Designation For Flu-Preventing Antiviral ↗
Via Stocktwits
News headline image
Top movers analysis one hour before the close of the markets on 2025-11-14: top gainers and losers in today's session. ↗
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Which stocks are moving on Friday? ↗
Intrigued by the market activity in the middle of the day on Friday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Gold Tumbles Over 2%; Cidara Therapeutics Shares Spike Higher ↗
 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday. 
Via Chartmill
News headline image
Merck Swoops In On Buyout Bonanza With A $9.2 Billion Cidara Therapeutics Deal ↗
The company is getting deeper into the antiviral space, buying a company working on a long-acting drug to protect against flu. 
Via Investor's Business Daily
News headline image
Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Nasdaq Dips Over 300 Points; Applied Materials Posts Upbeat Q4 Earnings ↗
 
Via Benzinga
News headline image
Merck Makes Big Bet On Flu Protection With Cidara Buyout ↗
Merck (NYSE: MRK) to acquire Cidara (NASDAQ: CDTX) for $9.2 billion, diversifying its portfolio with CD388. 
Via Benzinga
News headline image
Discover the top movers in Friday's pre-market session. ↗
Discover the top movers in Friday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Merck To Buy Cidara In $9.2B Deal To Strengthen Antiviral Portfolio ↗
With the new deal, Merck would gain access to CD388, currently in late-stage development, and designed to prevent influenza infection in individuals at higher risk of influenza complications. 
Via Stocktwits
Topics Intellectual Property
News headline image
Why RLX Technology Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Is Cidara Therapeutics (CDTX) Stock Trending Overnight? ↗
Cidara Therapeutics shares jumped over 42% in after-hours trading following a 13D filing and Phase 3 enrollment milestone. 
Via Benzinga
Cidara Therapeutics Stock Soars 42% After-Hours On Merck Buyout Buzz — Retail Traders Eye A Potential Blowout Premium ↗
Via Stocktwits
News headline image
Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Cidara Therapeutics Analyst Says Lead Influenza Candidate Is 'Strategically Attractive' ↗
JP Morgan initiated coverage on Cidara Therapeutics with Overweight rating & tgt of $200, citing lead flu asset CD388's game-changing potential. 
Via Benzinga
News headline image
Cidara Therapeutics Surges Ahead of ESWI 2025 Presentation and JP Morgan Coverage ↗
Cidara Therapeutics Inc (NASDAQ:CDTX) shares are trading higher on Friday after the biotech company made a recent announcement about their presentation at the upcoming ESWI 2025 conference. JP Morgan... 
Via Benzinga
News headline image
Why Cidara Therapeutics Stock Crushed It Today ↗
The company earned an important fast-track review designation for a pipeline medication. 
Via The Motley Fool
News headline image
Cidara Shares Are Trading Higher Friday: What's Going On? ↗
Cidara shares are trading higher Friday after the company secured $339 million in BARDA funding to advance its CD388 pandemic influenza therapeutic and onshore its manufacturing. 
Via Benzinga
News headline image
Why Cidara Therapeutics Was Such a Healthy Stock Today ↗
The company could have quite a winner on its hands with its most advanced pipeline drug. 
Via The Motley Fool
Lithium Americas, Alibaba, uniQure, IREN, Cidara: Stocks Making The Biggest Moves Today ↗
Via Stocktwits
News headline image
Why Cidara Therapeutics, Already Up 173% This Year, Just Hit A Five-Year High ↗
The company is accelerating plans to run Phase 3 testing of its non-vaccine flu prevention drug by six months. 
Via Investor's Business Daily
Topics Intellectual Property
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.